Health ❯ Healthcare ❯ Chronic Conditions

Obesity

Weight Management Treatment Options Type 2 Diabetes Health Risks Cardiovascular Health Weight Regain Hypertension Diabetes Treatment Strategies GLP-1 Medications

FDA Orders Post-Approval Safety Studies for Lilly’s Foundayo Weight-Loss Pill

Regulators cite a fast review plus a novel compound as reasons to seek longer-term safety data.

Amazon Pharmacy Launches Same-Day Delivery for Lilly’s Foundayo Weight-Loss Pill

Heart Attack Alerts Shift Toward Younger Adults as German Experts Push Prevention

UK Regulator Flags Rare Pancreatitis, Including Deaths, Tied to Wegovy and Mounjaro

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Oxford Review Finds GLP-1 Weight Loss Largely Lost Within About Two Years After Stopping

BMJ Review Finds Rapid Weight Regain After Stopping GLP-1 Weight-Loss Injections

Argentina Launches Lilly’s Mounjaro for Obesity and Diabetes After ANMAT Approval

Novo Nordisk Slashes Wegovy Price in India by Up to 37% to Take On Mounjaro

Hypertension in Mexico Is Hitting Younger Adults as Sonora Logs 2025 Increase

Triple-Dose Semaglutide Outperforms Standard Regimen in Weight-Loss Trials

Bariatric Surgery Outperforms GLP-1 Medicines Over 10 Years for Patients With Diabetes and Obesity

Metformin Linked to Lower Dementia and Mortality Risks in Overweight, Obese Adults

GLP-1 Weight-Loss Drugs Fail to Boost Fitness and Cause Significant Muscle Loss

Liraglutide Cuts Chronic Migraine Days by More Than Half

France to Let All Doctors Prescribe Wegovy and Mounjaro Starting June 23

Haryana Cuts Maternal Mortality Ratio by 17 Points to 89

NHS to Expand GP Prescriptions of Mounjaro for Weight Loss

UK to Trial Pharmacy-Based NHS Weight-Loss Jab Prescriptions

Nice Proposes Annual Weight Monitoring for Millions with Long-Term Health Conditions